| Feldman, Steven R |
NCT02659670: Internet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea |
|
|
| Recruiting | 4 | 20 | US | internet survey, brimonidine topical gel 0.33%, MIRVASO, brimonidine | Wake Forest University Health Sciences | Rosacea | 12/18 | 12/18 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
NCT05981118: Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) |
|
|
| Enrolling by invitation | 2/3 | 40 | US | Betamethasone dipropionate 0.05%, Tapinarof | Wake Forest University Health Sciences, Dermavant Sciences, Inc. | ICD10 Code L40.9 for Psoriasis | 07/25 | 12/25 | | |
| Active, not recruiting | 2 | 30 | US | ivermectin, digital interaction, digital interaction survey with ivermectin, GPSkin, GPSkin Barrier® | Wake Forest University Health Sciences, Galderma R&D | Rosacea | 03/25 | 11/25 | | |
| Recruiting | 1 | 72 | US | Adapalene Gel, Differin, Adapalene Gel and the clindamycin phosphate/benzoyl peroxide gel, Differin and ONEXTON, adapalene, benzoyl peroxide gel, and clindamycin phosphate gel every day., Differin, Epsolay, Clindamycin | Wake Forest University Health Sciences, Bausch Health Americas, Inc. | Acne | 05/25 | 11/25 | | |
| Not yet recruiting | 1 | 84 | US | Otezla - Standard Care, Apremilast, Reminder Text Intervention with apremilast, Otezla, Extended Consultation for apremilast | Wake Forest University Health Sciences, Amgen | Psoriasis | 09/25 | 12/25 | | |
NCT03465696: A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis |
|
|
| Active, not recruiting | N/A | 180 | US | Group #2 (Intervention), Group #3 (Intervention) | Wake Forest University Health Sciences | Psoriasis | 06/19 | 02/25 | | |
| Active, not recruiting | N/A | 67 | US | | Wake Forest University Health Sciences | Hidradenitis Suppurativa | 06/20 | 02/25 | | |
NCT04058652: Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study) |
|
|
| Active, not recruiting | N/A | 20 | US | transcutaneous electrical nerve stimulation (TENS) unit | Wake Forest University Health Sciences | Psoriasis | 02/25 | 04/25 | | |
NCT03168347: Assessing Patient Confidence in Biologic Medications |
|
|
| Active, not recruiting | N/A | 400 | US | Anecdotal Evidence, Research Study Evidence, Anecdotal + Research Study Evidence, No Evidence | Wake Forest University Health Sciences | Psoriasis | 05/25 | 12/25 | | |
| Recruiting | N/A | 40 | US | Text reminder | Wake Forest University Health Sciences, Bristol-Myers Squibb | Psoriasis | 07/25 | 12/25 | | |
| Active, not recruiting | N/A | 35 | US | Cetaphil Pro Eczema moisturizer, Electronic interaction, GPSkin | Wake Forest University Health Sciences, Galderma R&D | Xerosis Due to Atopic Dermatitis | 02/25 | 12/25 | | |
NCT03756792: Assessing Patient Anxiety During Mohs Micrographic Surgery |
|
|
| Active, not recruiting | N/A | 100 | US | Normal Education Material, Vignette | Wake Forest University Health Sciences | Anxiety | 07/25 | 12/25 | | |
| Recruiting | N/A | 30 | US | Demonstration of applying triamcinolone cream, Mobile App Use, Standard of Care | Wake Forest University Health Sciences | Atopic Dermatitis | 03/25 | 10/25 | | |
| Recruiting | N/A | 15000 | Europe, Canada, US | | Target PharmaSolutions, Inc. | Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria | 12/50 | 12/50 | | |
| Yosipovitch, Gil |
NCT04717466: Brain Changes in Psoriasis After Secukinumab Treatment |
|
|
| Active, not recruiting | 4 | 23 | US | Secukinumab | University of Miami, Novartis | Psoriasis, Healthy | 05/24 | 03/25 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis |
|
|
| Completed | 1 | 24 | Europe, US | CDX-0159, barzolvolimab, Normal saline | Celldex Therapeutics | Prurigo Nodularis | 07/23 | 07/23 | | |
|
